Coloplast stock rating cut, target slashed by Deutsche Bank

On Monday, Deutsche Bank (ETR:DBKGn) analysts adjusted their stance on Coloplast (CSE:COLOb) A/S (COLOB:DC) (OTC: CLPBY), downgrading the medical device company’s stock rating from Buy to Hold. Accompanying this change, the price target was significantly reduced to DKK 708 from the previous DKK 1,020. The stock, currently trading near its 52-week low of $9.67, has seen a 13.58% decline over the past year. InvestingPro data shows three analysts have recently revised their earnings estimates downward for the upcoming period.

The downgrade comes after Coloplast’s announcement that the anticipated profitability improvements for the year will not materialize or will be substantially less than expected. This revision follows a period where the company’s margins were impacted by a series of small-scale acquisitions and execution challenges. Despite these concerns, the company maintains a robust gross profit margin of 67.45% and has achieved 9.8% revenue growth in the last twelve months. Investors seeking deeper insights into Coloplast’s financial health can access comprehensive analysis through InvestingPro, which offers exclusive financial metrics and expert commentary.

Deutsche Bank’s analysts noted that another round of restructuring is on the horizon for Coloplast, which has cast doubts on management’s credibility. In light of these developments, the firm has revised its adjusted earnings per share (EPS) estimates downward by 2-3% for the fiscal year 2025 and beyond.

This reassessment is further influenced by the ongoing uncertainty in the Chinese ostomy market, which has contributed to the analysts’ decision to lower the target price-to-earnings (P/E) multiple to 25 times, down from 35 times. The reduced P/E multiple reflects the weaker-than-expected results and the upcoming restructuring, both of which add to the uncertainty surrounding the company’s performance.

The new price target of DKK 708 takes into account these various factors, including the anticipated impact of the restructuring and market challenges on Coloplast’s future earnings. As a result of these adjustments, Deutsche Bank has moved to a more cautious stance on the stock, shifting from a Buy to a Hold rating.

In other recent news, Coloplast A/S has seen notable updates from financial analysts. RBC Capital Markets upgraded Coloplast’s stock rating from Sector Perform to Outperform, raising the price target to DKK940. This change reflects an improved risk-reward balance, attributed to resolving operational challenges and a favorable outlook for profit margins. RBC Capital Markets also highlighted potential long-term earnings growth driven by reimbursement reforms and innovations like the Heylo Ostomy leak detection device. Meanwhile, JPMorgan upgraded Coloplast’s rating from Underweight to Neutral, setting a price target of DKK700. This adjustment considers the company’s valuation amidst past operational difficulties and a 47% decline since 2020. JPMorgan remains cautious about further stock appreciation, noting limited near-term catalysts. Both firms’ analyses suggest that Coloplast is addressing its recent challenges, with RBC Capital Markets showing a more optimistic outlook compared to JPMorgan.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.